Secondary Prevention of Atherosclerotic Events

Introduction to Secondary Prevention

The American College of Chest Physicians recommends secondary prevention of atherosclerotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease 1

Clopidogrel reduces the relative risk of myocardial infarction, ischemic stroke, or vascular death by 8.7% compared to aspirin in high-risk patients, according to the CAPRIE trial 1
Dual antiplatelet therapy with aspirin reduces the risk of cardiovascular events in patients with acute coronary syndromes and prevents stent thrombosis after coronary interventions 1
The American Heart Association recommends clopidogrel in association with aspirin for patients with non-ST-segment elevation acute coronary syndromes (NSTEMI/unstable angina) who are treated medically or undergo coronary revascularization, with a loading dose of 300 mg followed by 75 mg per day 2
The American Heart Association recommends clopidogrel in association with aspirin for patients with ST-segment elevation acute coronary syndromes (STEMI) who are treated medically, and as an alternative to prasugrel or ticagrelor when they are not available or are contraindicated 2
Clopidogrel is recommended as an alternative to aspirin in patients with a history of intolerance or contraindication to aspirin, with a strength of evidence level of high 3

Key pharmacokinetic properties of clopidogrel include:

Property	Description
Absorption	Rapid absorption after oral administration
Metabolism	Requirement of hepatic metabolism to form active metabolite
Binding	Irreversible binding to platelets
Onset of action	Antiplatelet effects beginning within 2 days
Maximum steady-state inhibition	Reached after 4-7 days of regular dosing

Clopidogrel functions as a prodrug that requires two-step hepatic metabolism through the cytochrome P450 enzyme system to generate its active metabolite, which then irreversibly binds to the platelet P2Y12 receptor, preventing ADP-induced platelet aggregation, as recommended by the American Heart Association and American College of Cardiology 1, 2, 4

The American Heart Association notes that prasugrel and ticagrelor are more potent than clopidogrel in acute coronary syndromes but have a higher bleeding risk 2
Newer P2Y12 inhibitors, such as prasugrel and ticagrelor, have shown greater reduction in cardiovascular events, faster onset of action, and more consistent antiplatelet effect, but also increased bleeding risk, according to the American College of Cardiology, with a strength of evidence level of high 2

High on-treatment platelet reactivity occurs in approximately one-third of patients prescribed clopidogrel, which is associated with a 1.5-fold to 5-fold increased risk of thrombotic events, according to the American College of Cardiology, with a strength of evidence level of moderate 1
Factors affecting response to clopidogrel include genetic polymorphisms, drug interactions, comorbidities, and concomitant medications, with a strength of evidence level of moderate 1, 5
The American Heart Association recommends genetic testing for CYP2C19 polymorphisms in high-risk patients, with a strength of evidence level of moderate 1

The European Society of Cardiology notes that proton pump inhibitors, especially omeprazole and esomeprazole, may reduce the effectiveness of antiplatelet therapy, and combining antiplatelet therapy with anticoagulants or NSAIDs increases the bleeding risk 6
The American College of Cardiology recommends that for elective procedures with high bleeding risk, clopidogrel should be discontinued 5-7 days before surgery, and for urgent CABG, interruption for at least 24 hours is recommended, with a strength of evidence level of high 2
The American College of Cardiology recommends that clopidogrel should be resumed 24-72 hours after surgery when bleeding risk is not excessive, with a strength of evidence level of high 2
Planning elective procedures with appropriate clopidogrel interruption when possible is recommended by the American College of Cardiology, with a strength of evidence level of high 2

The European Society of Cardiology recommends clopidogrel for the prevention of stent thrombosis after coronary stent implantation, with a duration of therapy varying depending on the type of stent and the patient's bleeding risk 7
The European Society of Cardiology recommends a duration of clopidogrel therapy of 12 months in association with aspirin for patients with acute coronary syndromes, and a variable duration depending on the type of stent and bleeding risk for patients with coronary stents 7